Discovery Labs developing former GSK facility into $500M healthcare, life sciences tech community

The Discovery Labs, which was formed by MLP Ventures, is developing a $500 million healthcare, life sciences and tech co-working community at the former GlaxoSmithKline facility in King of Prussia, Pennsylvania. (Discovery Labs)

The Discovery Labs, which was formed by MLP Ventures, is developing a $500 million healthcare, life sciences and tech co-working community at the former GlaxoSmithKline facility in King of Prussia, Pennsylvania.

When completed, the campus will feature a 1.6 million-square-foot collaborative laboratory as well as the 640,000-square-foot Innovation at Renaissance Campus. The idea is to turn the site into the world’s largest co-working “ecosystem” for healthcare, life sciences and tech-enabled companies.

GSK continues to operate a sterile injectables manufacturing plant on its East Campus in Upper Merion, Pennsylvania.

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

“The size of each Discovery Labs enables enterprise level companies to work side by side with startup and emerging companies and enjoy the benefits of the co-working phenomenon,” Audrey Greenberg, Discovery Labs' chief executive, said in a statement. “It is the first of a network of massive co-working properties which will encourage powerful, collaborative innovation on an international scale.”

GSK sold the site last year for a reported $77 million to O’Neill Properties, which later became MLP Ventures.

A major attraction at the campus will be a 100-square-foot incubator operated by the Pennsylvania Biotech Center that will be dubbed IQ Connect. The space will be designed to attract millennial workers by offering on-site coffee shops and restaurants, a $10 million conference center with a 275-seat auditorium and a fitness center that will offer yoga and Pilates classes. They also plan to include walking trails and an outdoor amphitheater.

Suggested Articles

Lonza is on deck to help manufacture AstraZeneca's COVID-fighting antibody duo at its Portsmouth, New Hampshire site.

Japanese regulators approved the manufacturing of Novartis' Kymriah at a Kobe site, adding the first Asian facility to the therapy's network.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.